Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): The CriTax study

Eerden, Ruben A.G. van; Atrafi, Florence; Vlieg, M.A.M. vanHylckama; Hoop, Esther Oomen–de; Bruijn, Peter de; Moelker, Adriaan; Lolkema, M.P.; Rijcken, Cristianne J.F.; Hanssen, Rob; Eskens, F.; Mathijssen, R.H.J.; Koolen, Stijn L.W.

doi:10.1093/annonc/mdz244.049

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molecules under 200 nm [53,54], such as nanotherapeutics, can accumulate there and avoid healthy tissue distribution. Although techniques to implement the EPR effect on humans are challenging and time consuming [55], it is possible to observe a 25% greater intratumor exposure in patients for docetaxel nanoparticles [56]. However, a recent review declared that this improved accumulation was very heterogeneous and only represented 0.7% of the administered dose, leaving room for optimization [57].…”

Section: Optimization Of Tumor Passive Targetingmentioning

confidence: 99%

Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?

2022

View full text Add to dashboard Cite

While the number of oncology-related nanotherapeutics and immunotherapies is constantly increasing, cancer patients still suffer from a lack of efficacy and treatment resistance. Among the investigated strategies, patient selection and combinations appear to be of great hope. This review will focus on combining nanotherapeutics and immunotherapies together, how they can dually optimize each other to face such limits, bringing us into a new field called nano-immunotherapy. While looking at current clinical trials, we will expose how passive immunotherapies, such as antibodies and ADCs, can boost nanoparticle tumor uptake and tumor cell internalization. Conversely, we will study how immunotherapies can benefit from nanotherapeutics which can optimize their lipophilicity, permeability, and distribution (e.g., greater tumor uptake, BBB crossing, etc.), tumor, tumor microenvironment, and immune system targeting properties.

show abstract

Section: Optimization Of Tumor Passive Targetingmentioning

confidence: 99%

Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?

2022

View full text Add to dashboard Cite

show abstract

“…81,82 More recently, improved tumor targeting with nanoparticles as compared with standard drugs was highlighted in a phase I study on CPC634, a polymeric docetaxel formulation which led to a near fourfold increase in tumor accumulation as compared with standard docetaxel in patients with solid tumors. 83 These clinical reports highlight how PK and distribution could be markedly improved using smart delivery systems as compared with standard treatments. Other drugs which can be cargoed by liposomal nanoparticles include irinotecan in pancreatic cancer, 84 or the cytarabine + daunorubicin doublet in acute myeloid leukemia.…”

Section: Developing Smart Delivery Systemsmentioning

confidence: 99%

Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations

Ferrer

Fanciullino

Milano

et al. 2020

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

The current trend to personalize anticancer therapies mostly relies on selecting the best drug or combination of drugs to achieve optimal efficacy in patients. In addition to the comprehensive genetic and molecular knowledge of each tumor before choosing the drugs to be given, there is probably much room left for improvement by further personalizing the very modes by which the drugs are given, once they have been carefully selected. In particular, shifting from standard dosing to tailored dosing should help in maintaining drug exposure levels in the right therapeutic window, thus ensuring that the efficacy/toxicity balance is optimal. This paper covers the current knowledge regarding pharmacokinetic/pharmacodynamic relationships of anticancer agents, from decades‐old cytotoxics to the latest immune checkpoint inhibitors, the most frequent sources for long‐neglected interpatient variability impacting on drug exposure levels, and what could be done to achieve real personalized medicine in oncology such as implementing therapeutic drug monitoring with adaptive dosing strategies or using model‐driven modalities for personalized dosing and scheduling.

show abstract

Polymer–drug and polymer–protein conjugated nanocarriers: Design, drug delivery, imaging, therapy, and clinical applications

Guo,

2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Polymer–drug conjugates and polymer–protein conjugates have been pivotal in the realm of drug delivery systems for over half a century. These polymeric drugs are characterized by the conjugation of therapeutic molecules or functional moieties to polymers, enabling a range of benefits including extended circulation times, targeted delivery, controlled release, and decreased immunogenicity. This review delves into recent advancements and challenges in the clinical translations and preclinical studies of polymer–drug conjugates and polymer–protein conjugates. The design principles and functionalization strategies crucial for the development of these polymeric drugs were explored followed by the review of structural properties and characteristics of various polymer carriers. This review also identifies significant obstacles in the clinical translation of polymer–drug conjugates and provides insights into the directions for their future development.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): The CriTax study

Cited by 4 publications

References 0 publications

Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?

Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?

Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations

Polymer–drug and polymer–protein conjugated nanocarriers: Design, drug delivery, imaging, therapy, and clinical applications

Contact Info

Product

Resources

About